print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISE

Explore the XIGDUO XR Mechanism of Action

Metformin + SGLT2 Inhibitor: Reduce and remove glucose with dual-action therapy

XIGDUO XR combines the experience of metformin XR with the innovation of a sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce and remove glucose in adults with type 2 diabetes mellitus.1

 
  • METFORMIN XRA biguanide, reduces hepatic glucose production and gut absorption and increases peripheral glucose uptake and utilization.1
  • DAPAGLIFLOZINA glucuretic, is an SGLT2 inhibitor that removes glucose via renal excretion.1

XIGDUO XR reduces and removes glucose with complementary MOAs1

LIVER Reduces hepatic glucose production1
MUSCLE Increases peripheral glucose uptake and utilization to improve insulin sensitivity1
INTESTINES Reduces intestinal absorption of glucose1
  • Metformin hydrochloride reduces glucose by improving glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose.1
KIDNEY Removes glucose by reducing reabsorption and increasing urinary glucose excretion1

HOW DAPAGLIFLOZIN REMOVES GLUCOSE

The function of SGLT2 in glucose reabsorption
SGLT2 plays a primary role in removing glucose from the kidney filtrate and transports it back into the bloodstream.1,2 sglt1
How dapagliflozin works
By inhibiting SGLT2, dapagliflozin reduces glucose reabsorption into the bloodstream, which results in the urinary excretion of glucose.1,3,4 sglt2

REMOVES ABOUT 280 CALORIES1,4 Dapagliflozin is not indicated for weight loss.
In a pharmacodynamic study, SGLT2 inhibition with dapagliflozin resulted in the excretion of approximately 70 grams of glucose (approximately 280 calories) in the urine per day at Week 12.1,5,* *In patients with type 2 diabetes. Results may vary. The efficacy of dapagliflozin is dependent on sufficient renal function. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2.
.
For adults with type 2 diabetes, in addition to diet and exercise

Start with more than monotherapy

XIGDUO XR was the first type 2 diabetes treatment to combine two antihyperglycemic agents, metformin XR and dapagliflozin, in an extended-release, once-daily formulation.

Vs metformin XR or dapagliflozin. VIEW CLINICAL RESULTS FOR XIGDUO XR